Link Identified between Inflammation and Depression
By LabMedica International staff writers Posted on 20 Jun 2018 |
Image: The FLOUstar optima plate reader (Photo courtesy of BMG Labtech).
It is well established that people with both type-1 and type-2 diabetes have an increased risk of developing depression, a debilitating mental health disorder with potentially serious consequences, but the causes remain poorly understood.
Depression in type-1 diabetes patients is associated with higher levels of the inflammatory protein galectin-3, which is a key protein involved in promoting inflammatory immune system responses that are needed to repair tissue damage throughout the body, in response to injury or disease.
Scientists at Lund University (Lund, Sweden) and their colleagues carried out a cross-sectional study that included 283 type-1 diabetes (T1D) patients (56% men, age 18-59 years, diabetes duration ≥1 year). Depression was assessed by Hospital Anxiety and Depression Scale depression subscale. Blood samples, anthropometrics and blood pressure were collected, supplemented with data from medical records and the Swedish National Diabetes Registry.
Galectin-3 was analyzed using a commercial human DuoSet enzyme linked immunosorbent assay (ELISA) and supplementary ancillary kit. The ELISA analysis was performed and absorbance was measured at 450-580 nm in a FLOUstar optima plate reader. Concentrations of unknown samples were calculated using a four parameter logistic regression curve. The intra-assay coefficient of variation for the analysis was 4.3%. Galectin-3 levels equal to or greater than. 2.562 µg/L, corresponding to the 85th percentile, was defined as high galectin-3.
The scientists found that the median (quartile1, quartile3) galectin-3 was 1.3 µg/L (0.8, 2.9) for the 30 depressed patients, and 0.9 µg/L (0.5, 1.6) for the 253 non-depressed. Depression was associated with high galectin-3 in all the 283 patients (Adjusted odds ratio (AOR) 3.5), in the 161 men (AOR 3.4), and in the 122 women (AOR 3.9). HbA1c, serum-lipids, serum-creatinine, blood pressure, obesity, smoking, physical inactivity, cardiovascular complications, and drugs (antihypertensive, lipid lowering, oral anti-diabetic drugs, and antidepressants) were not associated with high galectin-3.
The authors concluded that their study was the first to show an association between depression and galectin-3. Depression was the only explored parameter associated with high circulating galectin-3 levels in 283 T1D patients. High galectin-3 levels might contribute to the increased risk for Alzheimer’s disease, cardiovascular and all-cause mortality observed in persons with depression. Potentially, in the future, treatment targeting galactin-3 might improve the prognosis for patients with high galectin-3 levels. The study was published on May 14, 2018, in the journal Endocrine Connections.
Related Links:
Lund University
Depression in type-1 diabetes patients is associated with higher levels of the inflammatory protein galectin-3, which is a key protein involved in promoting inflammatory immune system responses that are needed to repair tissue damage throughout the body, in response to injury or disease.
Scientists at Lund University (Lund, Sweden) and their colleagues carried out a cross-sectional study that included 283 type-1 diabetes (T1D) patients (56% men, age 18-59 years, diabetes duration ≥1 year). Depression was assessed by Hospital Anxiety and Depression Scale depression subscale. Blood samples, anthropometrics and blood pressure were collected, supplemented with data from medical records and the Swedish National Diabetes Registry.
Galectin-3 was analyzed using a commercial human DuoSet enzyme linked immunosorbent assay (ELISA) and supplementary ancillary kit. The ELISA analysis was performed and absorbance was measured at 450-580 nm in a FLOUstar optima plate reader. Concentrations of unknown samples were calculated using a four parameter logistic regression curve. The intra-assay coefficient of variation for the analysis was 4.3%. Galectin-3 levels equal to or greater than. 2.562 µg/L, corresponding to the 85th percentile, was defined as high galectin-3.
The scientists found that the median (quartile1, quartile3) galectin-3 was 1.3 µg/L (0.8, 2.9) for the 30 depressed patients, and 0.9 µg/L (0.5, 1.6) for the 253 non-depressed. Depression was associated with high galectin-3 in all the 283 patients (Adjusted odds ratio (AOR) 3.5), in the 161 men (AOR 3.4), and in the 122 women (AOR 3.9). HbA1c, serum-lipids, serum-creatinine, blood pressure, obesity, smoking, physical inactivity, cardiovascular complications, and drugs (antihypertensive, lipid lowering, oral anti-diabetic drugs, and antidepressants) were not associated with high galectin-3.
The authors concluded that their study was the first to show an association between depression and galectin-3. Depression was the only explored parameter associated with high circulating galectin-3 levels in 283 T1D patients. High galectin-3 levels might contribute to the increased risk for Alzheimer’s disease, cardiovascular and all-cause mortality observed in persons with depression. Potentially, in the future, treatment targeting galactin-3 might improve the prognosis for patients with high galectin-3 levels. The study was published on May 14, 2018, in the journal Endocrine Connections.
Related Links:
Lund University
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines